Ethical considerations of early (first vs. second trimester) risk assessment disclosure for trisomy 21 and patient choice in screening versus diagnostic testing

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 145, Issue 1, 2007, Pages 99-104

  Sharma, Geeta ^a   McCullough, Laurence B ^b   Chervenak, Frank A ^{a,c,d,e,f,g,h,i,j,k,l}  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c International Society of the Fetus as a Patient

^d World Association of Perinatal Medicine

^e International Academy of Perinatal Medicine

^f Ian Donald Inter University School of Medicine and Ultrasound   (United States)

^g March of Dimes Bioethics Advisory Committee ^*

^h National Children's Study Federal Advisory Committee

ⁱ Italian Society of Obstetrics and Gynecology   (Italy)

^j Barcelona Society of Obstetrics and Gynecology   (Spain)

^k Texas Society of Obstetrics and Gynecology   (United States)

^l Academy of Medical Science in Croatia   (Croatia)

more..

Author keywords

Ethics; Risk assessment; Screening

Indexed keywords

AUTONOMIC DYSFUNCTION; DECISION MAKING; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INFORMED CONSENT; JUSTICE; MEDICAL ETHICS; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TRISOMY 21;

DOWN SYNDROME; ETHICS, MEDICAL; FEMALE; GENETIC TESTING; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; RISK ASSESSMENT;

EID: 33947284025     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.30118     Document Type: Review

References (27)

1. American College of Obstetricians and Gynecologists Practice Bulletin #27. 2001. Prenatal diagnosis of fetal chromosomal abnormalities. Obstet Gynecol 97: Suppl 1-12.
2. American College of Obstetricians and Gynecologists. 2002. Patient choice and the maternal-fetal relationship. Ethics in Obstetrics and Gynecology. Washington, D.C.: ACOG. p 61-63.
3. American College of Obstetricians and Gynecologists, Committee Opinion #296. 2004. First-trimester screening for fetal aneuploidy. Obstet Gynecol 104:215-217.
4. Berkowitz KL, Roberts J, Minkoff H. 2006. Challenging the strategy of maternal age-based prenatal genetic counseling. JAMA 295:1446-1448.
5. Chasen ST, Skupski DW. 2003. Ethical dimensions of nuchal translucency screening. Clin Perinatol 30:95-102.
6. Chasen ST, McCullough LB, Chervenak FA. 2004. Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population? Am J Obstet Gynecol 190:769-774.
7. Chervenak FA, McCullough LD. 1992. What is obstetric ethics? Clin Obstet Gynecol 35:709-719.
8. Chervenak FA, McCullough LB. 2005. Implementation of first-trimester risk assessment for trisomy 21: Ethical considerations. Am J Obstet Gynecol 192:1777-1781.
9. Chervenak FA, McCullough LB, Chasen ST. 2005. Clinical implications of the ethics of informed consent for first-trimester risk assessment for trisomy 21. Semin Perinatol 29:277-279.
10. De Graaf IM, Tijmstra T, Bleker OP, van Lith JM. 2002. Womens' preference in Down syndrome screening. Prenat Diagn 22:624-629.
11. Druzin ML, Chervenak F, McCullough LB. Blatman KN, Neidich JA. 1993. Should all pregnant patients be offered prenatal diagnosis regardless of age? Obstet Gynecol 81:615-618.
12. Kornman LH, Wortelboer MJM, Beekhuis JK, Morssink LP, Mantingh A. 1997. Women's opinions and the implications of first- versus second-trimester screening for fetal Down's syndrome. Prenat Diag 17:1011-1018.
13. Malone FD, Canick JA, Ball KH, Nyberg DA, Comstock CH, Bukowski K, Berkowitz KL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SK. Wolfe HM, Dukes K, Bianchi DW, Rudnicka AK, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME, First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. 2005. First-trimester or second-trimester screening, or both, for Downs syndrome. N Engl J Med 353:2001-2011.
14. Mulvey S, Wallace EM. 2006. Women's knowledge of and attitudes to first and second trimester screening for Down's syndrome. Brit J Obstet Gynecol 107:1302-1305.
15. Mulvey S, Zachariah K, McIlwaine K, Wallace EM. 2003. Do women prefer to have screening tests for Down syndrome that have the lowest screen-positive rate or the highest detection rate. Prenat Diagn 23:828-832.
16. Nicolaides KH. 2004. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 191:45-67.
17. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. 1992. Fetal nuchal transluccncy ultrasound screening for chromosomal defects in first trimester pregnancy. BMJ 304:867-869.
18. Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A. 2005. Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21. Am J Obstet Gynecol 193:322-326.
19. Reddy UM, Mennuti MT. 2006. Incorporating first-trimester Down syndrome studies into prenatal screening: executive summary of the National Institute of Child Health and Human Development workshop. Obstet Gynecol 107:167-173.
20. Sharma G, Gold HT, Chervenak FA, McCullough L, Alt AK, Chasen ST. 2005. Patient preference regarding first-trimester aneuploidy risk assessment. Am J Obstet Gynecol 193:1429-1436.
21. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 351:343-346.
22. Spencer K, Aitken D. 2004. Factors affecting women's preference for type of prenatal screening test for chromosomal anomalies. Ultrasound Obstet Gynecol 24:735-739.
23. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM, SURUSS Research Group. 2003. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 7:1-77.
24. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, Platt L, Mahoney M, Johnson A, Hogge WA, Wilson RD, Mohide P, Hershey D, Krantz D, Zachary J, Snijders R, Greene N, Sabbagha R, MacGregor S, Hill L, Gagnon A, Hallahan T, Jackson L, First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. 2003. First-trimester screening for trisomies 21 and 18. N Engl J Med 349: 1405-1413.
25. Wenstrom KD. 2005. Evaluation of Down syndrome screening strategies. Semin Perinatol 29:219-224.
26. Wray AM, Ghidini A, Alvis C, Hodor J, Landy HJ, Poggi SH. 2005. The impact of first-trimester screening on AMA patients' uptake of invasive testing. Prenat Diagn 25:350-353.
27. Zoppi MA, Ibba RM, Putzolu M, Floris M, Monni G. 2001. Nuchal translucency and the acceptance of invasive prenatal chromosomal diagnosis in women aged 35 and older. Obstet Gynecol 97:916-920.